AI in Pharma

Developing new drugs has historically been a lengthy and costly process with high failure rates. Fewer than 14% of drug candidates that enter phase 1 clinical trials receive FDA approval^[1]. Those that succeed typically require an average of 10-15 years and a $2.5 billion investment to reach the market^[2]. The result is that, on average, only 10% of drug development programs result in licensed drugs^[3]. Some argue those are not great odds! However, recent advancements in artificial intelligence promise to dramatically streamline this process.

But how exactly can AI increase the speed and efficiency of drug development?

Let’s first look at some of the current challenges in the drug development pipeline.

High Costs and Time-Consuming Processes
Traditional drug development involves extensive research, multiple phases of clinical trials, and regulatory approvals. Each phase is time-consuming – years - and expensive - billions of dollars.

High Failure Rates
Many potential drugs fail in clinical trials for numerous reasons - unforeseen side effects, lack of efficacy and appropriate biomarkers, and occasionally poor strategic planning. These and other issues can lead to substantial financial losses and delays in bringing new treatments to market.

Complex Data Management
The drug development process generates vast amounts of data from various sources, including biochemical experiments, clinical trials, and patient records. Managing and interpreting this data is a resource-heavy task.

Misunderstanding Underlying Disease Mechanisms
Understanding complete disease mechanisms presents huge challenges due to the complexity of biological systems, the diverse nature of diseases, and the limitations of current technology.

So, how can AI transform drug development?

Algorithmic computation can facilitate drug design and testing in multiple ways, with four areas currently identified as contributing most to reducing costs, time, and failure rates: accelerating discovery time, enhancing actual drug design, optimising and flexibly adapting clinical trials, and lastly managing the vast amount of data produced.

Accelerating Drug Discovery

Two separate but aligned techniques have the potential to speed up the entire end-to-end process, helping reduce costs and failure rates.

Predictive Modeling
AI and ML tools can rapidly identify novel compounds and targets and analyse biological data to predict how different compounds interact with target molecules. This predictive power helps identify promising drug candidates faster than traditional methods.

Virtual Screening
Chemical libraries now hold information on over a billion molecules, so more efficient virtual screening approaches are vital. AI can swiftly analyse these large databases to identify potential hit candidates.

Enhancing Drug Design

Although validation in experimental systems is still necessary to eliminate false leads from computer-aided molecular design, data-driven drug discovery is expected to improve the efficiency of drug development programs.

Structure-Based Drug Design
Rapidly predicting the three-dimensional structures of target proteins and how potential drugs will bind to them will enhance the precision of drug design.

Generative Models
Computational models can generate new molecular structures with the desired properties, creating novel drug candidates that traditional methods may not discover.

Pattern Recognition
Applying ML techniques makes it possible to uncover previously hard-to-find patterns, increasing the chances of success in later experimental stages. Importantly, the typical machine learning models used for this pattern discovery are entirely free from the hallucination issues that generative AI suffers from.

Optimising Clinical Trials

Targeted Recruitment
Analysing large datasets from medical records, genetic information, and social media ensures improved targeting of potential trialists by identifying those who meet specific trial criteria.

Adaptive trial designs
AI can monitor ongoing clinical trials in real-time, allowing trial designs to be modified based on interim results. This flexibility can lead to faster and, ultimately, more successful trials.

Improving Data Management and Analysis

Big Data Integration
By integrating and analysing large datasets from various stages of drug development, previously unattainable insights can be produced.

Real-Time Data Analysis
AI tools can process and analyse data in real-time, enabling quicker decision-making and reducing delays in the drug development pipeline.

Conclusion

AI promises to transform the drug development landscape by accelerating the discovery of new drugs, enhancing the design of drug candidates, optimising clinical trials, and improving data management. While there are still challenges to overcome, such as ensuring the accuracy of AI predictions and integrating AI into existing workflows, the potential benefits are too significant to ignore.